{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:14:45Z","timestamp":1760170485929,"version":"3.44.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.jneuroim.2008.05.029","type":"journal-article","created":{"date-parts":[[2008,7,30]],"date-time":"2008-07-30T04:32:45Z","timestamp":1217392365000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil"],"prefix":"10.1016","volume":"201-202","author":[{"given":"Sofie P.M.","family":"Janssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Phernambucq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Martinez-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H.","family":"De Baets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Losen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2008.05.029_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0966-3274(98)80015-4","article-title":"Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil","volume":"6","author":"Blaheta","year":"1998","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000050759","article-title":"Mycophenolate mofetil: a new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection","volume":"46","author":"Caponnetto","year":"2001","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.jneuroim.2008.05.029_bib5","doi-asserted-by":"crossref","first-page":"s46","DOI":"10.1191\/0961203305LU2118OA","article-title":"Mycophenolate mofetil and myasthenia gravis","volume":"14","author":"Ciafaloni","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00007890-199908150-00014","article-title":"Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines","volume":"68","author":"Cohn","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib8","first-page":"5","article-title":"The role of antibodies in myasthenia gravis","volume":"202","author":"De Baets","year":"2002","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib52","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1196\/annals.1254.033","article-title":"Immunoregulation in experimental autoimmune myasthenia gravis\u2013about T cells, antibodies, and endplates","volume":"998","author":"De Baets","year":"2003","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007691-200406000-00016","article-title":"Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy","volume":"26","author":"Derijks","year":"2004","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0192-0561(99)00037-5","article-title":"Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release","volume":"21","author":"Durez","year":"1999","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0140-6736(05)63084-X","article-title":"Treatment of pemphigus vulgaris with mycophenolate mofetil","volume":"350","author":"Enk","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib13","first-page":"15","article-title":"Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents","volume":"23","author":"Eugui","year":"1991","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection","volume":"345","author":"European Mycophenolate Mofetil Cooperative Study Group","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002277.pub2","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2006","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","article-title":"Therapeutic options in autoimmune myasthenia gravis","volume":"6","author":"Garcia-Carrasco","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1423.023","article-title":"Mycophenolate mofetil and atherosclerosis: results of animal and human studies","volume":"1110","author":"Gibson","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib18","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 8","key":"10.1016\/j.jneuroim.2008.05.029_bib19","first-page":"S117","article-title":"Therapy of rheumatoid arthritis with mycophenolate mofetil","volume":"11","author":"Goldblum","year":"1993","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib21","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0022-3565(24)34992-4","article-title":"Glutathione-dependent metabolism of cis-3-(9H-purin-6-ylthio)acrylic acid to yield the chemotherapeutic drug 6-mercaptopurine: evidence for two distinct mechanisms in rats","volume":"290","author":"Gunnarsdottir","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib22","first-page":"359","article-title":"Comparison of cyclosporin A and G with and without azathioprine regarding immunosuppressive efficacy, toxicity, and pharmacokinetics in Lewis rats","volume":"7","author":"Hagberg","year":"1988","journal-title":"J. Heart. Transplant."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jama.298.1.29","article-title":"Trials assess myasthenia gravis therapies","volume":"298","author":"Hampton","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.51.3.912-a","article-title":"Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil","volume":"51","author":"Hauser","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2249.1997.d01-881.x","article-title":"Age- and sex-related resistance to chronic experimental autoimmune myasthenia gravis (EAMG) in Brown Norway rats","volume":"107","author":"Hoedemaekers","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0165-5728(98)00126-X","article-title":"Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis","volume":"89","author":"Hoedemaekers","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(99)90078-7","article-title":"Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease","volume":"106","author":"Larkin","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archneur.63.8.1066","article-title":"Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders","volume":"63","author":"Lehmann","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib30","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1084\/jem.141.6.1365","article-title":"Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs","volume":"141","author":"Lennon","year":"1975","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1445-5994.2006.01222.x","article-title":"Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity","volume":"37","author":"Lim","year":"2007","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib33","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/awh612","article-title":"Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis","volume":"128","author":"Losen","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1196\/annals.1405.034","article-title":"Treatment of myasthenia gravis by preventing acetylcholine receptor modulation","volume":"1132","author":"Losen","year":"2008","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2353\/ajpath.2007.060676","article-title":"Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis","volume":"170","author":"Martinez-Martinez","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib36","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study","volume":"998","author":"Meriggioli","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(01)00478-6","article-title":"Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis","volume":"185","author":"Mowzoon","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gut.44.5.625","article-title":"Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease","volume":"44","author":"Neurath","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib39","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.V1091965","article-title":"Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement","volume":"10","author":"Nowack","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib40","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jocn.2005.12.008","article-title":"Mycophenolate mofetil \u2014 as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: the Singapore experience","volume":"14","author":"Prakash","year":"2007","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib43","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib44","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib45","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mus.20543","article-title":"Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases","volume":"34","author":"Schneider-Gold","year":"2006","journal-title":"Muscle. Nerve."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000050768","article-title":"Mycophenolate mofetil in the therapy of severe myasthenia gravis","volume":"46","author":"Schneider","year":"2001","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1749-6632.1976.tb47692.x","article-title":"Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects","volume":"274","author":"Seybold","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.coph.2005.01.010","article-title":"Myasthenia gravis: emerging new therapy options","volume":"5","author":"Sieb","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jneuroim.2008.05.029_bib49","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","author":"The Muscle Study Group","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.029_bib50","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1567-5769(01)00081-9","article-title":"Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis","volume":"1","author":"Tran","year":"2001","journal-title":"Int. Immunopharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.jneuroim.2008.05.029_bib51","doi-asserted-by":"crossref","first-page":"s12","DOI":"10.1191\/0961203305LU2112OA","article-title":"Mycophenolate mofetil in animal models of autoimmune disease","volume":"14","author":"Zandman-Goddard","year":"2005","journal-title":"Lupus"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572808002117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572808002117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:09:21Z","timestamp":1759046961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572808002117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":53,"alternative-id":["S0165572808002117"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.029","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}